News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Company News

Cardinal Health Partners with GlucoTec for Insulin Therapy with Alaris® System
11/18/2008

DUBLIN, Ohio, Nov. 18, 2008 — Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced an agreement with GlucoTec, Inc. to explore the use of proprietary technology from GlucoTec with the Alaris® System line of intravenous pumps to help improve the control of glucose levels in patients with hyperglycemia.

GlucoTec produces the Glucommander Plus (G+) glucose management system, which uses a sophisticated intravenous insulin dosing algorithm that is clinically proven to quickly and safely control hyperglycemia in hospital patients, while minimizing the risk of hypoglycemia. The ability to closely monitor and adjust insulin doses is known as tight glycemic control.

Hyperglycemia is a condition that exists when blood sugars are too high. While hyperglycemia is typically associated with diabetes, this condition can exist in many patients who don’t have diabetes, yet have elevated blood sugar levels caused by trauma or stress from surgery and other complications from hospital procedures. Insulin therapy is used to bring blood sugar levels back into a normal range.

Proper management of hyperglycemia through tight glycemic control has been clinically proven to result in improved patient outcomes in the form of decreased incidence of hospital acquired infections, renal failure, blood transfusions and mortality.

The GlucoTec G+ system operates through a computer at the bedside where a clinician sets the safe target glucose range for the individual patient. As glucose measurements are entered into the system, a corresponding insulin dose recommendation is calculated and then given to the patient. The insulin dose calculation is adaptive and based on many variables, including the patient’s response to previous doses. The system also provides many safety alarms and reminders for subsequent glucose checks.


About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients.  With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined™ electronic infection surveillance service, VIASYS® respiratory care products and the CareFusion™ patient identification system.  The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide.  Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents.  More information about the company may be found at cardinalhealth.com.

About GlucoTec
Headquartered in Greenville, South Carolina, GlucoTec is leading the way with next generation glycemic control management systems for the over 200 million diabetes patients worldwide. GlucoTec offers the only Glycemic management system designed to stabilize excursions and maintain glucose levels within a predefined target range utilizing a unique series of safety guardrails that allow patients to achieve normoglycemia quickly and safely, while minimizing the risk of cerebral edema, hypoglycemia, cardiac arrest, diabetic ketoacidosis (DKA), and neurological trauma. For more information about GlucoTec or to view additional press releases, please visit www.glucotec.com.

More Company News
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

04/07/2021

By Victor Crawford, Chief Executive Officer of the Pharmaceutical segment at Cardinal Health

04/07/2021

Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve...

03/30/2021

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will...

View all company news »

* Required Fields